XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Total revenues $ 47,831,000 $ 34,587,000
Cost of sales (15,524,000) (10,553,000)
Gross profit 32,307,000 24,034,000
Operating expenses:    
Selling, general and administrative 40,513,000 28,813,000
Research and development 3,026,000 2,149,000
Total operating expenses 43,539,000 30,962,000
Loss from operations (11,232,000) (6,928,000)
Other (expense) income:    
Interest expense, net (6,548,000) (5,415,000)
Investment loss from Eton Pharmaceuticals (1,248,000)
Other income, net 26,000
Total other expense, net (6,548,000) (6,637,000)
Net loss $ (17,780,000) $ (13,565,000)
Basic net loss per share of common stock $ (0.50) $ (0.38)
Diluted net loss per share of common stock $ (0.50) $ (0.38)
Weighted average number of shares of common stock outstanding, basic 35,826,452 35,469,638
Weighted average number of shares of common stock outstanding, diluted 35,826,452 35,469,638
Product Sales Net [Member]    
Revenues:    
Total revenues $ 47,745,000 $ 34,508,000
Other Revenues [Member]    
Revenues:    
Total revenues $ 86,000 $ 79,000